Podcasts

In episode 116, Dr. Greg Rippon, vice president and chief medical partner at Genentech, discusses his work in Alzheimer’s and his outlook for the future of the therapeutic space.

Raj Verma, chief diversity, culture, and experience officer at Sanofi, discusses the various ways people see diversity around the world and how companies should be building diversity, equity, and inclusion into a company’s everyday fabric.

Proximyl Health’s Halen Dang, VP, Creative Director of Art and Carrie Morris, VP, Creative Director of Copy discuss remote teamwork and how to successfully lead agency creative teams with hybrid schedules.

In episode 114, Tiago Reis Marques, MD, PhD, CEO of Pasithea Therapeutics, discusses why it’s important to manage high levels of workplace stress, and how companies can help employees in need.

The use of biometric data and novel digital biomarkers in the administration of CAR-T therapy can both improve the safety profile and reduce patient burden of cancer treatment. Jaydev Thakkar, Chief Operating Officer at Biofourmis, will share how this data paired with FDA-cleared algorithms can predict the onset of adverse events to allow for proactive intervention and improved patient outcomes.

In episode 113, Indranil Bagchi, senior vice president and worldwide head, value and access at Novartis, and member of Pharmaceutical Executive Editorial Advisory Board, discusses the challenges of reaching patients and what he believes can help improve the situation.

Carolyn O’Neill, Chief Creative Officer of Centron discusses their APEX-award winning global disease awareness campaign for both HCPs and patients, “Dimensionalizing the Patient Experience in PNH.” PNH or paroxysmal nocturnal hemoglobinuria is a rare immune disorder that attacks a person’s red blood cells. The campaign was meant to build on it is not an inherited disease and people’s symptoms don’t exhibit externally, usually appearing in mid-life and portray the feelings of a PNH sufferer.

In episode 112, Nima Farzan, CEO of Kinnate, who was one of Pharmaceutical Executive’s Emerging Pharma Leaders in 2013, discusses how he’s successfully navigated his career path, from building a foundation in pharma to growing his expertise in biotech.

Nexus Pharmaceuticals' Chief Strategy Officer Omair Ahmed discusses their APEX-award winning EMERPHED™ campaign, which built on the ideas of simplification, safety and stability to enhance their hospital-delivered product and support their field sales reps.

In episode 111, Kevin Ali, CEO of Organon, talks about how’s he’s lead the launch of a new niche company for women’s health, and what he hopes it can achieve.

Ken Winell, chief technology officer of Greater Than One, talks about the metaverse and the potential it has to serve the pharma industry.

CDM Princeton’s Senior Creative Vice President John England discuss the company’s APEX-award winning Ilumya campaign “Defy the Laws of Psoriasis,” which used multiple innovative ideas including an AR focused in-person interactive piece, a upward scrolling website and more.

Myrto Kontaxi, a partner in the Biopharma Sustainability Roundtable, and lead author on its updated Biopharma Investor ESG Communications Guidance; and Victoria Emerick, global head of sustainability strategy and operations at Bristol Myers Squibb, a Biopharma Sustainability Roundtable participant, and a key contributor to the Guidance development process, discuss the growing demand for better communication about ESG strategy and performance, and how the updated ESG Guidance can help both biopharma companies and investors respond.

Glue Advertising's Cindy Machles, CEO and Co-founder & Nate Whipple, Producer, discuss their APEX-award winning respiratory campaign "For My Lung Health" delivered through videos, SEM, and a website--in English and Spanish--as an educational initiative by ATS and CHEST to inform people of color about lung health.

In this podcast, co-founder and CTO of Emulate, Inc, discusses why now is the time for researchers to accelerate their transition from animal models to human relevant-science with Organ-on-chip technology. There is no doubt that animal models have contributed to major advances in medicine, however, a growing body of evidence suggests that animal models are seriously lacking in both sensitivity and specificity when it comes to predicting drug toxicity in humans. In a recent study published to bioRxiv, researchers found the human Liver-Chip to have an 87% sensitivity and 100% specificity when differentiating hepatotoxic from non-hepatotoxic small molecules. Importantly, all 22 hepatotoxic drugs included in the study had previously been classified as safe due to a lack of toxicity in animal models. Collectively, these compounds resulted in 208 patient fatalities and 10 liver transplants. Had the human Liver-Chip been used during preclinical screening of these compounds, it’s likely that many of these fatalities could have been avoided. By adopting organ-on-a-chip, you can help make the drug development process safer, more efficient and more humane.

In episode 108, the rest of the PharmExec editorial staff join Elaine and Miranda as they announce and give more insight into the profiles they've written about the eleven members of our 2022 Emerging Pharma Leaders.

Biolumina's Troy Clark, SVP, Creative Director, and Anne Brown, SVP, Creative Director, Copy discuss their APEX-award winning website "Be in the Know" for AstraZeneca's metastatic non-small cell lung cancer (NSCLC) disease state education efforts.

In episode 107, Camille Hertzka, VP, head of oncology US medical at AstraZeneca, talks about her experience as a leader in oncology over the years and to expect from the space moving into the future.

In episode 106, Christi Shaw, CEO of Kite, a Gilead Company, talks about how CAR T-cell therapies are impacting cancer care and the lessons she’s learned along her career path.

In episode 105, Rolf Hoenger,  area head of Latin America at Roche  Pharma, talks about the current pharma landscape in Latin America and his experiences as a leader in this area.

In episode 104, Susanne Schaffert, president of Novartis Oncology, discusses her career journey, which has combined both a passion for the arts and science, and how she believes the two can work together in pharma.

In episode 103, Robert Clarke, CEO and co-founder of Kinaset Therapeutics, talks about developing inhaled therapies to fight asthma and COPD, which is especially relevant as COVID-19 poses significant problems for sufferers.

In episode 102, Mike Devoy, chief medical officer of Bayer, also executive vice president of medical affairs and pharmacovigilance for Bayer’s Pharmaceuticals Division, discusses how innovation, including the digitalization of healthcare delivery, and breakthrough technologies can help people make the most out of the longer lives they’re living today.

As pricing transparency regulations and COVID-19 accelerate market disruption and changes in consumer behavior demand new engagement models, how can your organization prepare for the powerful shift toward more consumer-centric pricing transparency?

In episode 101, Bruno Larvol, CEO and founder of Larvol, discusses how he is invested in the digital world, both personally and professionally, and the impact it can have.

Our milestone 100th episode includes Lisa Henderson, group editorial director; Julian Upton, European and online editor; Fran Pollaro, senior editor; and Andy Studna, associate editor, discussing industry trends in areas such as Chinese biotech, corporate branding, psychedelic medicines, and market access barriers.

Bill Sibold, executive vice president and head of Sanofi Genzyme, talks about his work in specialty care over the past 10 years and what makes it unique.

Giacomo Chiesi, Head of Global Rare Diseases at the Chiesi Group, discusses what it has been like growing up around pharma, and how he’s turned a family passion into his own dedicated career path.

Mike Ward, Global Head of Thought Leadership in the Decision Resources Group at Clarivate, goes behind the numbers of our 2022 pipeline report and provides some interesting insights from the report provided by his company.

Tim Whitten, CEO and president of Taiho Oncology, discusses how innovative thinking—from developing new therapies to creating a podcast for employees during COVID—has played an important role in his professional journey.